Reduced T Cell and Antibody Responses to Inactivated Coronavirus Vaccine Among Individuals Above 55 Years Old

Imagem de Miniatura
Arquivos
art_MEDEIROS_Reduced_T_Cell_and_Antibody_Responses_to_Inactivated_2022.PDF (2.9 MB)
Citações na Scopus
17
Tipo de produção
article
Data de publicação
2022
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
SCAGION, Guilherme P.
CANDIDO, Erika D.
Citação
FRONTIERS IN IMMUNOLOGY, v.13, article ID 812126, 10p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
CoronaVac is an inactivated SARS-CoV-2 vaccine that has been rolled out in several low and middle-income countries including Brazil, where it was the mainstay of the first wave of immunization of healthcare workers and the elderly population. We aimed to assess the T cell and antibody responses of vaccinated individuals as compared to convalescent patients. We detected IgG against SARS-CoV-2 antigens, neutralizing antibodies against the reference Wuhan SARS-CoV-2 strain and used SARS-CoV-2 peptides to detect IFN-g and IL-2 specific T cell responses in a group of CoronaVac vaccinated individuals (N = 101) and convalescent (N = 72) individuals. The frequency among vaccinated individuals, of whom 96% displayed T cell and/or antibody responses to SARS-CoV-2, is comparable to 98.5% responses of convalescent individuals. We observed that among vaccinated individuals, men and individuals 55 years or older developed significantly lower anti-RBD, anti-NP and neutralization titers against the Wuhan strain and antigen-induced IL-2 production by T cells. Neutralizing antibody responses for Gamma variant were even lower than for the Wuhan strain. Even though some studies indicated CoronaVac helped reduce mortality among elderly people, considering the appearance of novel variants of concern, CoronaVac vaccinated individuals above 55 years old are likely to benefit from a heterologous third dose/booster vaccine to increase immune response and likely protection.
Palavras-chave
COVID-19, vaccine, CoronaVac, T cell responses, antibody, neutralizing antibody, age
URI
https://observatorio.fm.usp.br/handle/OPI/47002
Referências
  1. Aiello A, 2021, INT J INFECT DIS, V106, P338, DOI 10.1016/j.ijid.2021.04.034
  2. Alencar CH, 2021, TROP MED INFECT DIS, V6, DOI 10.3390/tropicalmed6030129
  3. Anderson EJ, 2020, NEW ENGL J MED, V383, P2427, DOI 10.1056/NEJMoa2028436
  4. Ansari A, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.636768
  5. Araujo DB, 2020, MEM I OSWALDO CRUZ, V115, DOI 10.1590/0074-02760200342
  6. Bajaj V, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.571416
  7. Brand I, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.688436
  8. Bueno SM., 2021, CLIN INFECT DIS, P1
  9. Cerqueira-Silva Thiago, 2022, Lancet Reg Health Am, V6, P100154, DOI 10.1016/j.lana.2021.100154
  10. Collier DA, 2021, NATURE, V596, P417, DOI 10.1038/s41586-021-03739-1
  11. Crooke SN, 2019, IMMUN AGEING, V16, DOI 10.1186/s12979-019-0164-9
  12. Deming ME, 2021, NAT MED, V27, P1510, DOI 10.1038/s41591-021-01463-x
  13. Dhume K, 2018, IMMUNOLOGY, V155, P53, DOI 10.1111/imm.12942
  14. Fernandez MA, 2021, CUAD ILUS ROMANT, P1, DOI 10.25267/Cuad_Ilus_romant.2021.i27.54
  15. Fiocruz, 2021, GISAID LINH SARS COV, P1
  16. Fish EN, 2008, NAT REV IMMUNOL, V8, P737, DOI 10.1038/nri2394
  17. Flanagan KL, 2017, ANNU REV CELL DEV BI, V33, P577, DOI 10.1146/annurev-cellbio-100616-060718
  18. Fonseca SG, 2006, AIDS, V20, P2263, DOI 10.1097/01.aids.0000253353.48331.5f
  19. Goodwin K, 2006, VACCINE, V24, P1159, DOI 10.1016/j.vaccine.2005.08.105
  20. Haq K, 2014, CURR OPIN IMMUNOL, V29, P38, DOI 10.1016/j.coi.2014.03.008
  21. Hartigan J. A., 1979, Applied Statistics, V28, P100, DOI 10.2307/2346830
  22. Jackson LA, 2020, NEW ENGL J MED, V383, P1920, DOI 10.1056/NEJMoa2022483
  23. Li JX, 2021, NAT MED, V27, P1062, DOI 10.1038/s41591-021-01330-9
  24. Marshall JC, 2020, LANCET INFECT DIS, V20, pE192, DOI 10.1016/S1473-3099(20)30483-7
  25. McElhaney JE, 2013, LANCET INFECT DIS, V13, P485, DOI 10.1016/S1473-3099(13)70046-X
  26. Murugesan K, 2021, CLIN INFECT DIS, V73, pE3130, DOI 10.1093/cid/ciaa1537
  27. Ni L, 2020, IMMUNITY, V52, P971, DOI 10.1016/j.immuni.2020.04.023
  28. Oliveira JR, 2021, IMMUNODOMINANT B CEL, DOI [10.1101/2021.03.11.21253399, DOI 10.1101/2021.03.11.21253399]
  29. Peckham H, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19741-6
  30. Ramasamy MN, 2020, LANCET, V396, P1979, DOI 10.1016/S0140-6736(20)32466-1
  31. Ranzani O, 2021, BMJ-BRIT MED J, V374, DOI 10.1136/bmj.n2015
  32. Richards NE, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.24331
  33. Seyahi E, 2021, RHEUMATOL INT, V41, P1429, DOI 10.1007/s00296-021-04910-7
  34. Swanson PA, 2021, SCI TRANSL MED, V13, DOI 10.1126/scitranslmed.abj7211
  35. Tan AT, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI152379
  36. Vacharathit V, 2021, LANCET INFECT DIS, V21, P1352, DOI 10.1016/S1473-3099(21)00568-5
  37. Victora C, 2021, ECLINICALMEDICINE, V38, DOI 10.1016/j.eclinm.2021.101036
  38. Wendel S, 2020, TRANSFUSION, V60, P2938, DOI 10.1111/trf.16065

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/19
Carregar mais